SCHEMBL3590127

SCHEMBL3590127

COC(=O)c1cc(C(=O)c2c(C)c(NC(=O)c3cccc(OC)c3)c3ccccn23)ccc1[N+](=O)[O-]

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.45
ALDH1A1 P00352 5/20 0.45
LMNA P02545 3/20 0.45
MAPK1 P28482 3/20 0.45
RXFP1 Q9HBX9 1/20 0.43
MEN1 O00255 4/20 0.42
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
TP53 P04637 1/20 0.42
PKM P14618 1/20 0.42
HPGD P15428 1/20 0.42
MAPT P10636 3/20 0.42
KDM4E B2RXH2 1/20 0.42
TSHR P16473 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6216569 0.94 KMT2A (0.45) KMT2AALDH1A1LMNAMAPK1RXFP1
SCHEMBL3605138 0.91 ALDH1A1 (0.46) KMT2AALDH1A1LMNAMAPK1RXFP1
SCHEMBL3608163 0.86 ALDH1A1 (0.44) KMT2AALDH1A1LMNAMAPK1MEN1
SCHEMBL150004 0.83 MAPT (0.46) KMT2AALDH1A1LMNARXFP1MEN1
SCHEMBL13918698 0.81 ALDH1A1 (0.39) KMT2AALDH1A1LMNAMAPK1RXFP1
SCHEMBL4498647 0.81 ALDH1A1 (0.41) KMT2AALDH1A1LMNAMEN1NPC1
SCHEMBL6217524 0.80 ALDH1A1 (0.44) KMT2AALDH1A1LMNAMAPK1MEN1
SCHEMBL4507657 0.79 HDAC3 (0.42) KMT2AALDH1A1LMNAMAPK1MEN1
SCHEMBL13918694 0.79 ALDH1A1 (0.38) KMT2AALDH1A1RXFP1MEN1SMN1; SMN2
SCHEMBL4507260 0.79 MAPT (0.38) KMT2AALDH1A1LMNAMAPK1RXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7803811-B2 1,2,3-substituted indolizine derivatives, inhibitors of FGFs, method for preparing them and pharmaceutical compositions containing them SANOFI-AVENTIS (FR) 2010-09-28 US disclosed
US-20090023770-A1 Novel 1,2,3-Substituted Indolizine Derivatives, Inhibitors of FGFs, Method for Preparing Them and Pharmaceutical Compositions Containing Them SANOFI-AVENTIS (FR) 2009-01-22 US disclosed
US-7442708-B2 1,2,3-substituted indolizine derivatives, inhibitors of fgfs, method for making same and pharmaceutical compositions containing same SANOFI-AVENTIS (FR) 2008-10-28 US disclosed
CN-100413863-C 1,2, 3-substituted indolizine derivatives, FGF inhibitors, process for preparing them and pharmaceutical compositions containing them SANOFI AVENTIS (FR) 2008-08-27 CN disclosed
US-20050203126-A1 Novel 1,2,3-substituted indolizine derivatives, inhibitors of fgfs, method for making same and pharmaceutical compositions containing same SANOFI (FR) 2005-09-15 US disclosed
CN-1649867-A Novel 1,2, 3-substituted indolizine derivatives, FGF inhibitors, process for preparing them and pharmaceutical compositions containing them SANOFI AVENTIS (FR) 2005-08-03 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050203126-A1 Novel 1,2,3-substituted indolizine derivatives, inhibitors of fgfs, method for making same and pharmaceutical compositions containing same FGFR3, FGFR1, NTRK3 KMT2A 4249/4885ALDH1A1 1784/4885LMNA 4129/4885
US-20090023770-A1 Novel 1,2,3-Substituted Indolizine Derivatives, Inhibitors of FGFs, Method for Preparing Them and Pharmaceutical Compositions Containing Them FGF2, FGF1, FGFR1 KMT2A 3830/4885ALDH1A1 1502/4885LMNA 3251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.